The FDA has approved a fixed-dose combination tablet consisting of sitagliptin and simvastatin, two drugs previously approved for type 2 diabetes and hypercholesterolemia. The new drug will be marketed as Juvisync by Merck. "This is the first product to combine a type 2 diabetes drug with a cholesterol lowering drug in one tablet," said Mary ...